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We have recently established a cancer-reactive human monoclonal antibody, GAH, with a positive ratio of over 90% against stomach
cancer. GAH was formulated as polyethyleneglycol (PEG)-modified immunoliposomal doxorubicin (DXR) (ILD) and its efficacy was
examined against gastrointestinal human cancers. In in vitro studies, a comparison of ILD with PEG-modified liposomal DXR (LD)
demonstrated that ILD had dose-dependent cytotoxicity for GAH-reactive B37 cancer cells, but not LD. In concordance with this
result, microscopic observations showed that ILD was bound to and GAH-dependently internalised by B37 cells. In in vivo studies, ILD
exhibited significantly greater antitumour activity on cancer xenograft models than LD or free DXR. The relation between efficacy
and antigen density was examined on 10 xenograft models bearing cancer cells with varying GAH reactivity. Immunoliposomal
doxorubicin therapeutic activity correlated with the antigen density, with a minimum number being required. Also, ILD revealed
strong antitumour activity on cancers with low sensitivity to DXR or LD, suggesting that ILD overcame the DXR resistance of
antigen-positive cancer cells. Thus, these results show that GAH endows liposomes with targeting activity, resulting in strong efficacy
against gastrointestinal cancers.
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Antibody-based targeting is a promising approach to the devel-
opment of targeted cancer therapy (Bator and Reading, 1991), and
liposomes are good candidates for drug delivery vehicles.
Entrapping drugs in liposomes not only prolongs the drug
circulation time but also changes the drug distribution in vivo.
Moreover, significant progress has been made as a result of the
development of liposomes modified with polyethyleneglycol
(PEG), because they are taken up less by the reticuloendothelial
system, thereby increasing their circulation time in the blood and
their accumulation in tumours (Papahadjopoulos et al, 1991;
Gabizon, 1992; Gabizon et al, 1994). Consequently, selective
delivery of drugs to target cells can be achieved by liposomes
tagged with antibodies that recognise specific determinants on the
target cells (Ahmad et al, 1993; Park et al, 1995; Huwyler et al,
1997). Tumour-cell-specific antibody-conjugated immunolipo-
somes therefore can serve as drug vehicles with both liposome-
and antibody-based targeting ability. We previously reported a
specific therapeutic effect of anti-AFP and anti-CEA mouse
monoclonal antibody (MAb)-conjugated liposomes containing
doxorubicin (DXR) for an AFP-producing hepatoma (Konno
et al, 1987) and a CEA-positive tumour (Uyama et al, 1994),
respectively. These, and many other studies, have revealed the
qualitative selectivity of immunoliposomes. Nevertheless, there has
been no detailed report demonstrating a quantitative relationship
between their therapeutic ability and the density of the antigens
recognised by the conjugated antibody in vivo. We recently
developed a human MAb (hu-MAb), GAH, which is highly reactive
to human cancers, and in particular has an over 90% positive ratio
against gastric cancer (Hosokawa et al, 2001). We report the
construction of GAH-conjugated PEG-modified liposomal DXR
(ILD) for cancer-targeting therapy and describe the cytotoxic
activity of ILD and its targeting ability in a cell-surface-GAH-
binding-site-density-dependent manner in both in vitro and in
vivo studies against human xenografts.
MATERIALS AND METHODS
Chemicals
Iminothiolane and 3(4,5-dimethylthiazoyl-2-yl)2,5 diphenyl tetra-
zolium bromide (MTT) were purchased from Sigma (Tokyo,
Japan). 2,4,-bis-(PEG)-6-chloro-s-triazine, average PEG molecular
weight of 5000, was obtained from Seikagaku Kogyo, KK (Tokyo,
Japan). The two-chain-type PEG 2-[4,6-bis-(PEG)-1,3,5-triazin-2-
ylamino]-3-mercapto-propionic acid was synthesised from L-
cystine and 2,4,-bis-(PEG)-6-chloro-s-triazine (Figure 1). A solid
lipid mixture consisting of dipalmitoylphosphatidylcholine, cho-
lesterol and maleimidated dipalmitoyl-phosphatidylethanolamine
(18:10:0.5 molar ratio) were obtained from NOF Corporation
(Tokyo, Japan). Doxorubicin hydrochloride was obtained from
Kyowa Hakko Co., Ltd (Tokyo, Japan).
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GAH (IgG1, k)-producing cells were established by the hybridoma
technique (Hosokawa et al, 2001). In brief, lymphocytes obtained
from a colon cancer patient were fused with P3U1 mouse myeloma
cells to produce hybridomas. A hybridoma expressing an antibody,
GAH, was selected based on cancer cell-specific reactivity against
viable cancer cells by flow cytometric analysis. Reactivity was also
confirmed by immunostaining of formalin-fixed cancer tissue
sections. The results showed high rates of GAH reactivity to cells
obtained from gastric cancer tissues and to gastric cancer tissue
sections (490%). The gene for GAH was cloned and expressed in
Chinese hamster ovary cell to obtain a stable antibody-producing
cell.
Preparation of ILD and liposomal DXR (LD)
The F(ab0)2 fragments of GAH (F(ab0)2/GAH) were prepared by
pepsin digestion of the intact GAH. The F(ab0)2/GAH was thiolated
with iminothiolane (Traut et al, 1973). Immunoliposomal doxor-
ubicin was prepared as depicted in Figure 1, essentially in the
manner as described by Suzuki et al (1995) with some modifica-
tions. Briefly, the solid lipid mixture was hydrated to form
multilamella liposomes and sized by passage through polycarbo-
nate membrane filters (Nucleopore; Microscience) of sequentially
smaller defined pore sizes, from 0.2 to 0.1mm. After DXR was
loaded into the liposomes using the pH gradient method (Nichols
and Deamer, 1976; Mayer et al, 1985), thiolated F(ab0)2/GAH and
then PEG were conjugated with the liposomes through thioether
linkage, respectively (Suzuki et al, 1995). Immunoliposomal
doxorubicin was purified using Sepharose CL-6B to remove
unincorporated DXR, unbound F(ab0)2/GAH and PEG. The
incorporated amounts of the F(ab0)2/GAH and the PEG were
determined by HPLC and these were 0.2 and 0.8mg per 1mg of
DXR (10mg in terms of total lipids), respectively. The final lipid
concentration was typically 5–10mgml
 1. The liposome size was
measured with an ELS-800 dynamic light scattering instrument
(Otsuka Electronics Co. Ltd, Osaka, Japan). The mean ILD size was
143nm (ranging from 125 to 160nm). Liposomal DXR was
prepared in the same way as ILD, except for the antibody
conjugation step. The incorporated amount of PEG was 0.8mg per
1mg of DXR (10mg in terms of total lipids) and the mean size was
131nm (ranging from 123 to 140nm). Stability of the formulations
was similar; it was found that the leakage from both formulations
was less than 3% during 2h incubation at 371C or 2 weeks at 41Ci n
phosphate-buffered saline (PBS) (pH 7.4) determined by the
method of Li et al (1998). The size change of both liposome
formulations was less than 10nm after the incubation periods.
Cell lines
Human colon cancer cell lines Caco-2, DLD-1 and SW620 were
obtained from the American Type Culture Collection, WiDr-Tc
(human colon cancer cell line) and TE-8 (human oesophagus
cancer cell line) were obtained from Tohoku University, Cell
Resource Center (Miyagi, Japan). Human stomach cancer cell lines
HSC-3, MKN-1 and MKN-45, and human rectum cancer cell line
SW837 were obtained from IBL Co., Ltd (Gunma, Japan). B37 cells
were established from a human stomach tumour (Hosokawa et al,
2001). Human venous endothelial cells (HUVECs) were obtained
from Cell Systems Corporation (Kirkland, WA, USA).
Animals
Male Balb/cAJcl-nu mice (4–5 weeks old) were obtained from
Nihon Clea Co. (Tokyo, Japan) and were kept in standard housing.
All animal studies were carried out according to the guidelines for
the care and use of experimental animals, drawn up by the





































Figure 1 Preparation schemes for ILD and LD. Polyethyleneglycol and antibody were conjugated to liposomes through thioether linkage. Liposomal DXR
was prepared in the same way as ILD, except for the antibody conjugation step. DPPC, dipalmitoylphosphatidylcholine; DPPE, dipalmitoylpho-
sphatidylethanolamine.
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sCorporation, which meet the ethical standards required by the law
and the guidelines about experimental animals in Japan.
In vitro comparison of the cytotoxic activity of ILD and LD
B37 cells were seeded on a 96-well plate (Costar) at 5 10
3well
 1.
After 1 day of culture, the cells were incubated for 1h at 371C with
ILD or LD diluted with normal human serum to a DXR
concentration of 0–10mgml
 1. The cells were then washed with
medium and cultured for 6 days with 10% FCS-containing
medium. Viable cells were detected by MTT assay (Green et al,
1984).
GAH-reactivity-dependent cytotoxic activity of ILD
B37 cells and HUVECs were cultured to confluence. Immunolipo-
somal doxorubicin or free DXR was added to the cells at a DXR
concentration of 1mgml
 1, and the cells were cultured for 2 more
days. The cells were examined through a microscope for viability.
Internalisation of ILD by cancer cells
ILD was labelled with PKH2 (Zynaxis Cell Science, Inc., Malvern,
PA, USA), which emits green fluorescence and has a high affinity
for the lipid bilayers generally used for membrane labelling (Horan
et al, 1990). Immunoliposomal doxorubicin was incubated with
PKH2 labelling solution for 10min at 601C. Unbound PKH2 was
removed with a NAP-10 column. Cultured B37 cells were reacted
with 20mgml
 1 of labelled ILD, according to the DXR concentra-
tion, for 1h at 41C without or with free F(ab0)2/GAH at a
concentration of 0.5mgml
 1. For an additional control, the cells
were incubated together with free human IgG F(ab0)2. After
another 1h incubation at 371C, the cells were washed and fixed
with 2% paraformaldehyde. Then the cells were examined for the
distribution of green fluorescence under a confocal fluorescence
microscope (LSM-510, Carl Zeiss) equipped with an argon laser.
In vivo therapeutic studies
Subcutaneous (SC) model Male Balb/cAJcl-nu mice were inocu-
lated subcutaneously on the back with one million MKN-45 cells.
When the tumour xenografts were fully established (11 days after
implantation), mice were assigned to different treatment groups.
Liposomal DXR or ILD was administered intravenously (i.v.) three
times at weekly intervals at a DXR equivalent dose of 2.2mgkg
 1.
Free F(ab0)2/GAH (0.36mgkg
 1) mixed with LD was injected using
the same schedule. The control group was treated with saline. The
tumour size was measured with a caliper and the weight was
calculated as 1
2 length width
2 (Geran et al, 1972). The ratio of
the estimated tumour weights compared to those of the first day
was determined and compared for each group.
Subrenal capsule (SRC) tumour model Male Balb/cAJcl-nu mice
were implanted under the renal capsule (Bennett et al, 1985) with a
few mm
3 pieces of cancer xenografts of HSC-3, B37, WiDr-Tc,
SW837, TE-8, Caco-2, DLD-1, SW620, MKN-1 and MKN-45, which
had been prepared from SC passages. The mice were divided into
four groups, and treatment was started the next day (day 1). The
experimental groups of mice received three i.v. injections,
3.0mgkg
 1, of free DXR, ILD or LD, respectively, at 6-day
intervals (on days 1, 8 and 15). The control group was treated with
saline. The tumours were excised and weighed on day 22.
Statistical method
Differences in in vivo antitumour activity were analysed by
Dunnett’s two-tailed test. All statistical analyses were conducted
with an SAS System statistical program, version 6.12 (SAS
Institute, Inc., NC, USA).
Quantitative measurement of cancer cell surface antigens
Viable cells were isolated from tumour tissues transplanted to
nude mice. In brief, fresh tumour tissue was minced with a razor
blade and suspended in medium. The suspension was passed
through a nylon mesh and centrifuged to remove the necrotic
debris. The separated cells were allowed to react with FITC-labelled
GAH at a concentration of 50mgml
 1 on ice for 60min. These cells
were washed and resuspended in PBS containing propidium iodide
(PI). FITC and PI fluorescence intensities per cell were measured
with a flow cytometer (FCM) (FACS 440 or BD-LSR; Becton/
Dickinson). Dead cells with PI fluorescence due to incorporation of
PI into their nuclei were excluded from the data. The number of
GAH molecules bound to the viable cell surface was calculated
using fluorescent latexes with known FITC-bound molecule
numbers (Flow Cytometry Standard) as standards.
RESULTS
Role of GAH conjugation in liposome-mediated cytotoxic
activity of ILD on cancer cells
First, to confirm the function of GAH conjugation to liposomes,
the activities of ILD and LD against GAH-reactive B37 cells were
compared using MTT assay. The ILD showed strong dose-
dependent cytotoxicity for B37 cells, despite the short-term
treatment, whereas the LD had no significant toxicity in the dose
range used (Figure 2). These results indicate that ILD exerts its
cytotoxic activity through GAH conjugated to the liposome
surface.
Internalisation of ILD by cancer cells
In order to identify the mechanism of the reaction between ILD
and cancer cells, cultured B37 cells were incubated with PKH2-
labelled ILD. The fluorescence distribution was then examined.
Confocal microscopy visualised an accumulation of intracellular
fluorescence in the cells incubated with ILD (Figure 3A). This
intracellular accumulation was inhibited by the addition of free
GAH (Figure 3B), whereas hardly any inhibition was observed in a
control experiment using human IgG (Figure 3C). This showed
that the cancer cells internalised the ILD and that the internalisa-


























Figure 2 Comparison of the antiproliferative activity of ILD and LD
against B37 cells. Cells in a 96-well plate were exposed to ILD (K)o rL D
(’) at the doses indicated, and the relative cell growth was determined by
MTT assay. Each value is the mean7s.d. of four determinations except at
the DXR concentration of 1.25mgml
 1 (n¼3).
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sComparative efficacy of ILD on HUVEC and cancer cells
GAH is known to be unreactive to normal tissues and cells
including HUVECs. To determine the tumour vs normal efficacy of
ILD, cell viabilities of B37 and HUVECs were compared after 2
days of culture with ILD or free DXR at a concentration of
1mgml
 1, which is a convincing concentration range based on
clinical DXR dosage. Free DXR was cytotoxic against both B37 cells
and HUVECs (Figure 3C and F). On the contrary, ILD showed no
significant cytotoxicity on GAH-non-reactive HUVECs (Figure 4E),
comparable to a drug-free control (Figure 4D), while the
cytotoxicity of ILD against B37 cells was remarkable (Figure 4B).
These findings indicate that ILD has GAH-reactivity-dependent
cytotoxicity.
Efficacy of ILD against antigen-positive gastric cancer
evaluated with xenograft models
The therapeutic effect of ILD was examined on MKN-45 human
gastric cancer xenograft models because MKN-45 has been used
for in vivo evaluation of immunoliposomes (Uyama et al, 1994)
with excellent reproducibility, and it has a high GAH antigen
expression level. The antitumour efficacy of ILD was compared
with those of free DXR or LD with an MKN-45 SRC xenograft
model. The result showed that ILD activity was significantly
greater than that of DXR or LD (Figure 5A). When ILD activity was
compared with that of LD on an MKN-45 SC model (Figure 5B),
significantly higher antitumour activity of ILD was confirmed in
concordance with the SRC result. Furthermore, LD mixed with free
GAH (0.36mgkg
 1) was administered for an additional compar-
ison. As a result, supplementation with free GAH gave no
distinguishable difference in LD antitumour activity, indicating
Figure 3 Internalisation of ILD. Cultured B37 cells were reacted with
PKH2-labelled ILD for 1h at 41C without (A) or with free F(ab0)2/GAH at
a concentration of 0.5mgml
 1 (B), about 100 times the amount of
antibody bound on liposomes, as well as with free human IgG F(ab0)2 (C)
for a control. After another 1h incubation at 371C, the cells were washed
and fixed and then examined under a confocal fluorescence microscope.
Scale bar: 10mm.
Figure 4 GAH-reactivity-dependent cytotoxicity of immunoliposomes.
B37 cells (A–C) or HUVECs (D–F) were cultured for 2 days with ILD
(B, E) or free DXR (C, F)a t1mgml
 1 in terms of DXR concentration.
(A) and (D) show drug-free controls for B37 and HUVECs, respectively.
Cell viability was assessed microscopically. Scale bar: 5mm.
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sthat the ILD antitumour effect resulted from the conjugation of the
antibody onto liposomes, and not synergistic activities of LD and
antibody, nor the result of modulation of drug sensitivity caused
by antibodies.
Estimation of number of bound GAH per viable cancer cell
To analyse the relation between the antitumour activity of these
formulations and the number of antigens, the number of bound
GAH molecules per viable cancer cell (designated as Ag density)
was determined by the FCM analysis described above. The average
numbers for each cancer cell line were as follows: Caco-2, 3.9 10
4
cell
 1; DLD-1, 5.5 10
4 cell





 1; SW837, 9.9 10
4 cell





 1; MKN-1, 1.0 10
5 cell
 1; MKN-45, 1.2 10
5
cell
 1; and B-37, 1.1 10
5 cell
 1.
Quantitative evaluation of the effect of antigen density on
ILD activity in the in vivo model
The relation between antitumour activity and Ag density was
examined using 10 human cancer cell lines on SRC models.
Tumour weights, as a result of treatment with ILD, LD or DXR in
each cancer model, were obtained in the same manner as for MKN-
45 SRC xenograft. From these values, tumour growth inhibition
(TGI) for each drug was calculated as follows: (1 (average tumour
weight of a drug treatment group)/(average tumour weight of a
control group)) 100. Figure 6A depicts TGIs for ILD or LD
against Ag density on each cancer. A correlation was found
between Ag density and TGI treated with ILD (Figure 6A, closed
circle), while no statistical relation between TGI with LD and Ag
density was observed (Figure 6A, open triangle). In particular, ILD
showed antitumour activity superior to that of LD against cancer
cells when Ag density was 41 10
5 cell
 1, whereas the superiority
of ILD over LD was not observed on Caco-2 (cell line numbered 1
in Figure 6), for which the number was as low as 3.9 10
4 cell
 1.
Liposomal DXR showed lower efficacy against many of the cell
lines tested, but excellent efficacy against a few of them (Figure 6A).
Hence, the activities of both liposomal formulations were further
analysed in terms of DXR sensitivity on each cancer cell tested in
vivo; TGI treated with DXR was used as an index for this sensitivity
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Figure 5 Comparison of therapeutic effects of ILD, LD and free DXR.
On SRC models (A), ILD, LD or free DXR was injected three times i.v.,
with 3.0mgkg
 1 in terms of DXR, into nude mice (n¼6) bearing MKN-45.
The antitumour effect of ILD was significantly higher than that of LD
(Po0.05) or DXR (Po0.01). Bars: means7 s.e. MKN45 cells implanted in
SC (B) were treated with LD (m, n¼13), ILD (K, n¼12), free F(ab0)2/
GAH (0.36mgkg
 1) mixed with LD (n, n¼6), at a DXR equivalent dose
of 2.2mgkg
 1, or saline (~, n¼12), by i.v. injections on the 3 days
indicated (m). Change in tumour weight was determined over the
treatment period. The antitumour effect of ILD was significantly higher than
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Figure 6 Quantitative GAH-binding-site-density-dependent effect of
ILD. SRC models were established with 10 cancer cell lines having different
numbers of GAH binding sites, as noted in the experimental section. These
nude mice were treated with drugs in the same manner as described in
Figure 5. From the results of each therapeutic experiment, tumour TGI
observed with ILD or LD was plotted against the number of GAH-binding
sites (A) or against DXR sensitivities (B), which were expressed as tumour
TGIs obtained with free DXR. Open triangles, LD; closed circles, ILD
against antigen-positive cells. In B, the open circle is a result of ILD against
Caco-2 cells, which were regarded as a antigen-negative control. Numbers
next to symbols show the data points from the following cancer cells: 1,
Caco-2; 2, DLD-1; 3, HSC-3; 4, SW620; 5, SW837; 6, MKN-1; 7, B-37; 8,
MKN-45; 9, TE-8 and 10, WiDr-Tc.
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sactivity was likely to be reflected in DXR sensitivity, unlike ILD
(Figure 6B). In other words, LD activity might be limited by DXR
sensitivity of cancer cells, while ILD would be likely to surpass the
limit and able to overcome the drug resistance of those cells when
they have enough Ag density. Against DLD-1 (numbered 2 in
Figure 6) or Caco-2, ILD showed modest TGIs, which were plotted
among the data points of LD activity. It was thought that the
minimum Ag density required for this immunoliposome to
overcome the DXR resistance of cancer cells was more than the
density of Caco-2 cells (Figure 6B, open circle).
DISCUSSION
In order to utilise the newly established human antibody GAH
fully, the antibody was formulated as an immunoliposome system
where F(ab0)2/GAH, with Fc portion removed, and PEG were
incorporated into the surface of liposomes containing DXR. This
novel immunoliposome was evaluated in vitro and in vivo against
gastrointestinal cancers.
GAH dependency on the character of ILD was revealed by the
selective cytotoxicity against B37 cells as well as the internalisation
by these cells in the in vitro studies (Figures 2 and 3). Also, ILD did
not show nonspecific cytotoxicity to the antigen-negative HUVECs
(Figure 4). Although the endothelial uptake of liposomes is
reported (Papadimitriou and Antimisiaris, 2000; Laverman et al,
2001), this formulation was found to be substantially inert with the
normal cells, but active with the target cells.
In the in vivo study, enhanced ILD activity was shown with both
the conventional SC model and the SRC model, on which it has
been demonstrated that many human tumours grow well and
retain the morphology and characteristics of the parent tumours
(Aamdal et al, 1985). Liposomal DXR showed a modest, but better
antitumour effect compared with free DXR in all gastric cancer
xenograft models tested, which could be attributable to enhanced
liposomal accumulation in tumour tissue (Papahadjopoulos et al,
1991), known as passive targeting. However, it is also known that
liposomes localise in the tumour extracellular compartment and
are not taken up by tumour cells (Gabizon, 1992; Huang et al,
1992), suggesting that the LD acts as a local depot of DXR.
On this point, Park et al (1997) and we (Maruyama et al, 1997)
revealed distribution of liposomes with tumour xenograft models,
showing that antibody conjugation on liposomes does not
necessarily lead to increased tumour accumulation over plain
liposomes. It is postulated that the accumulation of (immuno)li-
posomes was governed by passive diffusion and extravasation
from tumour blood vessels, and that improved antitumour activity
of immunoliposomes over plain liposomes can be explained by the
differences in intratumoral localisation or internalisation (Park
et al, 1997). In fact, when evaluated using a B37 xenograft model,
GAH immunoliposomes led to the accumulation of a similar
amount of DXR in tumour mass as LD did. In order to clarify the
role of GAH antibody for immunoliposomal targeting against solid
tumour, we examined the efficacy of ILD against tumour cell lines
having a variety of antigen densities.
We found ILD activity superior against stomach and colorectal
cancers in vivo; the activity of ILD correlated well with cell-surface-
GAH-binding site density (Figure 6A). Together with the fact that
ILD internalised against target cells (Figure 3), superior therapeu-
tic activity of ILD was thought to result from passive targeting as
well as active targeting, the effect of GAH conjugation. These
results also suggest that in order to exert an immunoliposomal
targeting effect fully, a minimum Ag density might be required; it
seemed that the threshold lay between 1 10
4 and 1 10
5 cell
 1,
determined by the method mentioned herein. In concordance with
these observations, Kirpotin et al (1997) showed antigen-density-
dependent targeting of anti-Her2 immunoliposomes in vitro. More
recently, Park et al (2002) demonstrated that anti-Her2 immuno-
liposomes exhibit excellent antitumour efficacy in vivo against
Her2-overexpressing breast tumour cells, while the efficacy was
almost the same as that of nonimmunoliposomes against low-
Her2-expressing MCF-7 cells (1 10
4 receptorcell
 1). In view of
DXR sensitivity, our results suggested that ILD could overcome
DXR resistance of cancer cells in vivo (Figure 6B). We actually
observed that ILD possesses therapeutic efficacy against DXR-
insensitive stomach cancer cells, which express a multidrug
resistance gene (data not shown). This property would have
special importance in treating gastrointestinal cancers clinically, as
they often show drug resistance against many types of anticancer
drugs. The evidence that ILD was internalised by the target cells
might serve as one avenue for enabling immunoliposomes to
overcome the drug resistance, as demonstrated by Suzuki et al
(1997) that an immunoliposome targeting transferrin receptor
(internalising receptor) modulates DXR resistance in DXR-
resistant human leukaemia cells.
GAH-conjugated immunoliposome characteristics are thought
to depend on GAH characteristics. It has been suggested that GAH
recognises a molecule related to cytoskeletal components present
on the surfaces of cancer cells. Investigators have recently shown
that modified cytokeratin molecules (Ditzel et al, 1997) or
vimentin-like protein (Nasoff et al, 1997) is present on the surface
of some malignant cells, and they are recognised by hu-MAbs
produced by cancer patients’ lymphocytes. The extent and nature
of these unique antigens are being investigated, and they are
expected to become targets of immunoconjugates for cancer
therapy as shown here.
We showed that GAH endows liposomes with targeting activity,
and allows for their internalisation by cancer cells. These
properties could result in strong efficacy and might be able to
overcome the drug resistance of cancer cells. Together with its high
positive ratio against stomach cancer, we believe that this
immunoliposome could be a versatile drug-targeting tool for the
treatment of gastrointestinal cancers.
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